Capital Investment Advisors LLC lowered its stake in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) by 5.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,996 shares of the exchange traded fund’s stock after selling 549 shares during the quarter. Capital Investment Advisors LLC owned 0.83% of ProShares Ultra Nasdaq Biotechnology worth $506,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Jane Street Group LLC increased its position in shares of ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock worth $306,000 after acquiring an additional 374 shares during the period.
ProShares Ultra Nasdaq Biotechnology Trading Up 3.7 %
Shares of BIB stock opened at $50.82 on Thursday. The firm has a fifty day moving average price of $55.73 and a 200 day moving average price of $61.08. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $47.19 and a 12 month high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Further Reading
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- 3 Healthcare Dividend Stocks to Buy
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Using the MarketBeat Dividend Yield Calculator
- How Do Stock Buybacks Affect Shareholders?
- 3 Monster Growth Stocks to Buy Now
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding BIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report).
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.